PATENT

To be assigned thousand the transfer of the tr IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Neuman et al.

Serial No.:

09/774,791

Examiner:

Confirmation No. 2627

Art Unit:

Filed:

February 1, 2001

For:

SYSTEM AND METHOD FOR CREATING PRESCRIPTIONS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08 for the above-identified patent application.

[X]	In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.				
[]	In accordance with 37 C.F.R. §1.97(c), also enclosed is:				
	[] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or				
	[] a statement as specified in 37 C.F.R. §1.97(e).				
	In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.				
[]	Check No in the amount of \$ for the total fee is attached.				
[]	Please charge \$ to Deposit Account No. 50-1283 for the total fee. This paper is being submitted in duplicate.				

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-1283.

Dated: <u>August 9, 2001</u>

Cooley Godward LLP ATTN: Patent Group One Freedom Square Reston Town Center 11951 Freedom Drive Reston, VA 20190-5601

Tel: (703) 456-8000 Fax: (703) 456-8100

103920 v1/RE 286_01!.DOC Respectfully submitted, COOLEY GODWARD LLP

By:

Jeffrey A. Pade Reg. No. 42,970

In re application of Neuman et al.

Serial No.:

Confirmation No. 2627

Art Unit:

2166

Filed:

February 1, 2001

For:

SYSTEM AND METHOD FOR CREATING PRESCRIPTIONS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached [X]Form PTO/SB/08 is enclosed.

This Information Disclosure Statement is filed within any one of the following time periods:

[]	within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
[]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
[X]	before the mailing date of a first office action on the merits; or
[]	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

Attorney Docket No. ISCR007/00US Serial No. 09/774,791 Page 2

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: August 9, 2001

Respectfully submitted, COOLEY GODWARD LLP

Cooley Godward LLP ATTN: Patent Group One Freedom Square Reston Town Center 11951 Freedom Drive Reston, VA 20190-5601

Tel: (703) 456-8000 Fax: (703) 456-8100 By:

Jeffrey A. Pade Reg. No. 42,970

PTO/SR/08 A	(08-00

				Str. ME		
Sub	stitute for form 14	49A/PT	0	& TRAUC	Complete if Known	
				Application Number	09/774,791	
INFORMATION DISCLOSURE				Filing Date	February 1, 2001	
ST	STATEMENT BY APPLICANT			First Named Inventor	Neuman et al.	
				Group Art Unit	2166	
	(use as many si	heets as	s necessary)	Examiner Name	not assigned	<u> </u>
Sheet	1	of	2	Attorney Docket Number	ISCR007/00US	

<u>-</u>	U.S. PATENT DOCUMENTS						
Examiner Initials*		U.S. Patent D	ocument		Date of Publication of Cited		
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY		
	Pl	5,561,446		Montlick	10-01-1996		
	P2	5,737,539		Edelson et al.	04-07-1998		
	P3	5,884,273		Sattizahn et al.	03-16-1999		
		·					
	<u> </u>						
	ļ						
			ļ				
	<u> </u>		_				
	}						
	 	<u> </u>					
	-						
			-	_			
			-				
	1		<u> </u>	-			
	1	†		+			
	 						
	†						

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite No. ¹	F	Foreign Patent Doc	ument	N	Date of Publication	
Initials*		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited of	of Cited Document MM-DD-YYYY	T ⁶
]						
		+					
	1						
	†	 					
	 	 			· · · · · · · · · · · · · · · · · · ·	 	

Examiner		Date				
Signature		Considered	_			
*EVALUED	Trivialise seems to the seems t		MDED COO	Direction of the second of	itatian ikaas ia s	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indicated on the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

				TRADE		
					Complete if Known	2
Substit	tute for form 14	149B/PT	О	Application Number	09/774,791	70
				Filing Date	February 1, 2001	6 % CA
INF	ORMATIC	DN DI	ISCLOSURE	First Named Inventor	Neuman et al.	8 6
STATEMENT BY APPLICANT				Group Art Unit	2166	0, 7, 4,
(use as many sheets as necessary)		Examiner Name	not assigned	ST ST		
Sheet	2	of	2	Attorney Docket Number	ISCR007/00US	8m 1/2

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	' 2
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	8
Initials*	No.1	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CI	FRANCIS B. PALUMBO et al., "Drug Use Evaluation", Principals and Practices of Managed Care Pharmacy, Academy of Managed Care Pharmacy, 1999, Chapter 5, pp. 51-60	
	C2	RENEE T. KUBACKA, "A Primer on Drug Utilization Review", Journal of the American Pharmaceutical Association, 1996, Vol. NS36, No. 4, pp. 257-261 and 279	
 	C3	WILLIAM N. YATES, JR. MS, et al., "A Drug Utilization Evaluation Primer: Conceptual and Operational Aspects", Group Health Association of America Annual Meeting, June 23-26, 1991	
	C4	APhA Special Report, "Opportunities for the Community Pharmacist in Managed Care", American Pharmaceutical Association, 1994	
	C5	American Society of Health Systems Pharmacists, "ASHP Statement on the Pharmacist's Clinical Role in Organized Health-Care Settings", American Journal of Hospital Pharmacy, 1989, Vol. 46, pp. 805-806	
	C6	LEE BOWMAN, "Drug Use Evaluation is DUE: Healthcare Utilization Evaluation is Over-DUE, Hospital Pharmacy, 1996, Vol. 31, No. 4, pp. 347-353	
	C7	Academy of Managed Care Pharmacy, "Concepts in Managed Care Pharmacy Series - Pharmaceutical Care" 1997	
	C8	Academy of Managed Care Pharmacy, "Concepts in Managed Care Pharmacy – Drug Use Evaluation" 1999	
	C9	The Joint Commission on Accreditation of Healthcare Organizations, "Comprehensive Accreditation Manual for Hospitals", 1995	<u> </u>

ı	Examiner	Date	
- 1	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.